Childhood Cancer Clinical Trials and Research

Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, actively participates in pediatric oncology clinical trials and research. Norton Children’s Cancer Institute is a long-standing member of the Children’s Oncology Group, the world’s largest group of hospitals treating children with cancer. These hospitals follow the same best practices, protocols and therapy regimens for childhood cancer treatment. This means children from across the country have access to the same clinical trials offering the latest treatments while working to decrease possible long-term effects.

Norton Children’s Cancer Institute also is part of the Beat Childhood Cancer research consortium. The consortium is a group of 40-plus universities and children’s hospitals offering a worldwide network of childhood cancer research trials coordinated by Helen DeVos Children’s Hospital in Grand Rapids, Michigan.

These trials are based on the work of a group of researchers connected with laboratory programs that develop new therapies for high-risk pediatric cancers — all with the goal of finding a cure.

Open trials available via Beat Childhood Cancer

Active Clinical Trials at Norton Children’s Cancer Institute

Learn more about participating in a clinical trial.

Active clinical trials at Norton Children’s Cancer Institute and the UofL School of Medicine include:

Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L

A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L

An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases

Acute Myeloid Leukemia (AML)

A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

B-Acute Lymphoblastic Leukemia (B-ALL)

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

B-Acute Lymphoblastic Leukemia (B-ALL)

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl

B-Acute Lymphoblastic Leukemia (B-ALL)

AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Behavior

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer

Central Nervous System Germ Cell Tumors (CNS GCT)

Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Classical Hodgkin Lymphoma (cHL)

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667).

Genomics

NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL

Germ Cell Tumors

AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Germ Cell Tumors

A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Heart Failure

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Hepatic Malignancy

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

High-Grade Glioma

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND #145355)

Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

COG ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR)

Langerhans Cell Histiocytosis

International Collaborative Treatment Protocol For Children And Adolescents With Langerhans Cell Histiocytosis

Leukemia

Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Leukemia

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia

Low-Grade Glioma (LGG)

A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Low-Grade Glioma (LGG)

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis

Medulloblastoma

NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYC

Medulloblastoma

Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Neuroblastoma

Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

Neuroblastoma

PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO mainten

Neuroblastoma

A Phase II Preventative Trial of DFMO as a Single Agent in Patients with High Risk Neuroblastoma in Remission (NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO))

Neuroblastoma

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Philadelphia Chromosome Ph+ALL

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.

Sickle Cell Disease (SCD)

A Comparative Effectiveness Study of Peer Mentoring [PM] versus Structured Transition Education Based Intervention [STE] for the Management of Care Transitions in Emerging Adults with Sickle Cell Disease (SCD)

Soft Tissue Sarcoma

A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)

Solid Tumors

Phase 1 Study To Evaluate The Safety And Pharmacokinetics Of Palbociclib (Ibrance®) In Combination With Irinotecan And Temozolomide In Pediatric Patients With Recurrent Or Refractory Solid Tumors

Solid Tumors

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Cancer – 7725

Norton Children’s Cancer Institute

Talk to a member of our care team about advanced pediatric cancer care.

Call (502) 629-7725


Request an Appointment Online

Haploidentical blood marrow transplant patient reaches milestones, celebrates turning 18

On Valentine’s Day, 2020, Angel Florian received a 6-foot-tall plush rose from her boyfriend. It was a substitute for the real flowers he wanted to give her but couldn’t because her weakened immune system made […]

Read Full Story

Teen’s ‘got this’ after bone cancer surgery

Jennifer Paschal, like most teens, has many interests. The 13-year-old, who lives in Southern Indiana, enjoys spending time with her large family. She loves animals and has many pets. She likes to draw and paint, […]

Read Full Story

What to expect after a childhood cancer diagnosis

The mixture of emotions that emerges with a new childhood cancer diagnosis can cause overwhelming feelings in both the child and the family. Childhood cancer treatment has evolved from a sole focus on medical treatment […]

Read Full Story

‘Go Gold’ to support kids with cancer

Kids’ cancer diagnoses haven’t stopped during the COVID-19 pandemic and neither has their fight. September is Childhood Cancer Awareness Month and the time of the year when Norton Children’s Cancer Institute, affiliated with UofL School […]

Read Full Story

$1.5 million in support to fund innovative pediatric cancer research

Louisville philanthropist Tom Dunbar will provide support up to $1.5 million to the Norton Children’s Hospital Foundation for pediatric cancer research at Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine. This gift […]

Read Full Story
Related Stories

Haploidentical blood marrow transplant patient reaches milestones, celebrates turning 18

On Valentine’s Day, 2020, Angel Florian received a 6-foot-tall plush rose from her boyfriend. It was a substitute for the real flowers he wanted to give her but couldn’t because her weakened immune system made […]

Read Full Story

Teen’s ‘got this’ after bone cancer surgery

Jennifer Paschal, like most teens, has many interests. The 13-year-old, who lives in Southern Indiana, enjoys spending time with her large family. She loves animals and has many pets. She likes to draw and paint, […]

Read Full Story

What to expect after a childhood cancer diagnosis

The mixture of emotions that emerges with a new childhood cancer diagnosis can cause overwhelming feelings in both the child and the family. Childhood cancer treatment has evolved from a sole focus on medical treatment […]

Read Full Story

‘Go Gold’ to support kids with cancer

Kids’ cancer diagnoses haven’t stopped during the COVID-19 pandemic and neither has their fight. September is Childhood Cancer Awareness Month and the time of the year when Norton Children’s Cancer Institute, affiliated with UofL School […]

Read Full Story

$1.5 million in support to fund innovative pediatric cancer research

Louisville philanthropist Tom Dunbar will provide support up to $1.5 million to the Norton Children’s Hospital Foundation for pediatric cancer research at Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine. This gift […]

Read Full Story

Search our entire site.